Summary
The introduction of tandem mass spectrometry has unquestionably been the most striking recent advance in newborn screening. A single test is applied for the simultaneous diagnosis of a number of disorders, making it possible to screen for some disorders that might otherwise have seemed too rare. Current screening is for disorders of metabolism of amino acids, organic acids and fatty acids. Assay performance for detection of disorders appears very good, but rarity of disorders, varied definitions and systems for follow-up and lack of databases for inborn errors of metabolism diagnosed clinically means that there is as yet insufficient information about most disorders. The technology can be applied to a much wider range of compounds, and the field looks set to expand. A key feature of newborn screening programmes must be the assessment of outcomes, and a major reason for the lack of uniformity in the approach adopted in different countries is the paucity of information on this. The available evidence points to overall advantages flowing from early diagnosis by screening, with reduction in mortality and morbidity. More studies are clearly needed and some are under way. The next new group of disorders already proposed for newborn screening is the lysosomal storage disorders. Attitudes may be changing about what it is desirable to include in a newborn screening programme, and this will indeed pose new ethical dilemmas.
Similar content being viewed by others
Abbreviations
- MCAD:
-
medium-chain acyl-CoA dehydrogenase deficiency
- MSUD:
-
maple syrup urine disease
- PPV:
-
positive predictive value
- PKU:
-
phenylketonuria
References
Allard P, Grenier A, Korson MS, Zytkovicz TH (2004) Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 37: 1010–1015.
American College of Medical Genetics Newborn Screening Panel (2006) Newborn screening: toward a uniform screening panel and system—executive summary. Pediatrics 117: S296–S307.
Andresen BS, Dobrowolski SF, O’Reilly L, et al (2001) Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 68: 1408–1418.
Bhattacharya K, Khalili V, Wiley V, Wilcken B (2006) Newborn screening may fail to identify intermediate forms of maple syrup urine disease. J Inherit Metab Dis 29: 586.
Boneh A, Andresen BS, Gregersen N, et al (2006) VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. Mol Genet Metab 88: 166–170.
Carpenter K, Wiley V, Wilcken B (2006) The impact of expanded screening on diagnostic and clinical biochemical genetics services in New South Wales, Australia. J Inherit Metab Dis 29: 17.
Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF (1993) Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem 39: 66–71.
Chace DH, Hillman SL, Millington DS, Kahler SG, Roe CR, Naylor EW (1995) Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem mass spectrometry. Clin Chem 41: 62–68.
Frankenburg WK, Chen JH, Thornton SM (1988) Common pitfalls in the evaluation of developmental screening tests. J Pediatr 113: 1110–1113.
Frazier DM, Millington DS, McCandless SE, et al (2006) The tandem mass spectrometry newborn screening experience in North Carolina: 1997–2005. J Inherit Metab Dis 29: 76–85.
Garg U, Dasouki M (2006) Expanded newborn screening of inherited metabolic disorders by tandem mass spectrometry: clinical and laboratory aspects. Clin Biochem 39: 315–332.
Gelb MH, Turecek F, Scott CR, Chamoles NA (2006) Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for newborn screening of lysosomal disorders. J Inherit Metab Dis 29: 397–404.
Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ (2006) The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med 8: 205–212.
Hardy DT, Hall SK, Preece MA, Green A (2002) Quantitative determination of plasma phenylalanine and tyrosine by electrospray ionization tandem mass spectrometry. Ann Clin Biochem 39: 73–75.
Hoffmann GF, von Kries R, Klose D, et al (2004) Frequencies of inherited organic acidurias and disorders of mitochondrial fatty acid transport and oxidation in Germany. Eur J Pediatr 163: 76–80.
Kaye CI, Accurso F, La FS, et al (2006) Introduction to the newborn screening fact sheets. Pediatrics 118: 1304–1312.
Koeberl DD, Millington DS, Smith WE, et al (2003) Evaluation of 3-methylcrotonyl-CoA carboxylase deficiency detected by tandem mass spectrometry newborn screening. J Inherit Metab Dis 26: 25–35.
Meikle PJ, Grasby DJ, Dean CJ, et al (2006) Newborn screening for lysosomal storage disorders. Mol Genet Metab 88: 307–314.
Millington DS, Kodo N, Norwood DL, Roe CR (1990) Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis 13: 321–324.
Naylor EW, Chace DH (1999) Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. J Child Neurol 14(Supplement 1): S4–S8.
Nennstiel-Ratzel U, Arenz S, Maier EM, et al (2005) Reduced incidence of severe metabolic crisis or death in children with medium chain acyl-CoA dehydrogenase deficiency homozygous for c.985A > G identified by neonatal screening. Mol Genet Metab 85: 157–159.
Pedersen CB, Bischoff C, Christensen E, et al (2006) Variations in IBD (ACAD8) in children with elevated C4-carnitine detected by tandem mass spectrometry newborn screening. Pediatr Res 60: 315–320.
Pollitt R (2006) International perspectives on newborn screening. J Inherit Metab Dis 29: 390–396.
Rashed MS, Ozand PT, Bucknall MP, Little D (1995) Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Pediatr Res 38: 324–331.
Rhead WJ (2006) Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: a global perspective. J Inherit Metab Dis 29: 370–377.
Rhead WJ, Allain D, Van Calcar S, et al (2002) Short chain acyl-CoA dehydrogenase (SCAD) and 3-methylcrotonyl-CoA caboxylase (MCC) deficiencies: tandem mass spectrometry newborn screening detects many clinically benign cases. J Inherit Metab Dis 25: 4.
Schulze A, Mayatepek E, Hoffmann GF (2002) Evaluation of 6-year application of the enzymatic colorimetric phenylalanine assay in the setting of neonatal screening for phenylketonuria. Clin Chim Acta 317: 27–37.
Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann GF (2003) Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 111: 1399–1406.
Simon E, Fingerhut R, Baumkotter J, Konstantopoulou V, Ratschmann R, Wendel U (2006) Maple syrup urine disease: favourable effect of early diagnosis by newborn screening on the neonatal course of the disease. J Inherit Metab Dis 29: 532–537.
van Maldegem BT, Duran M, Wanders RJ, et al (2006) Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency. JAMA 296: 943–952.
Waisbren S, Albers S, Amato S, et al (2003) Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 290: 2564–2572.
Wilcken B (2006) Mini-Symposium: Newborn screening for inborn errors of metabolism—clinical effectiveness. J Inherit Metab Dis 29: 366–369.
Wilcken B, Wiley V, Hammond J, Carpenter K (2003) Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 348: 2304–2312.
Wilcken B, Haas M, Joy P, et al (2007) Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. Lancet 369: 37–42.
Wiley V, Carpenter K, Wilcken B (1999) Newborn screening with tandem mass spectrometry: 12 months’ experience in NSW Australia. Acta Paediatrica Supplement 88: 48–51.
Ziadeh R, Hoffman EP, Finegold DN, et al (1995) Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res 37: 675–678.
Zytkovicz TH, Fitzgerald EF, Marsden D, et al (2001) Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem 47: 1945–1955.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Verena Peters
Competing interests: None declared
Rights and permissions
About this article
Cite this article
Wilcken, B. Recent advances in newborn screening. J Inherit Metab Dis 30, 129–133 (2007). https://doi.org/10.1007/s10545-007-0538-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-007-0538-6